Bibliographical noteFunding Information:
Conflict of interest: C.C. Moor reports grants and lecture payments from Boehringer Ingelheim, outside the submitted work. R.L.M. Mostard reports personal fees from Boehringer Ingelheim, Roche and Galapagos, outside the submitted work. J.C. Grutters has nothing to disclose. P. Bresser has nothing to disclose. M.S. Wijsenbeek reports grant payments to institution from the Netherlands Organization for Health Research and Development during the conduct of the study; grant, contract payments, consulting fees, lecture payments and advisory board payments to institution from Boehringer Ingelheim, Hoffman la Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Patient Association, The Thorax Foundation, ErasmusMC, Sarcoidosis.nl, Galapagos, Bristol Myers Squibb, Galecto, Respivant, Novartis, Savara; support for attending meetings from Boehringer Ingelheim and Hoffman la Roche, outside the submitted work; and holds the following unpaid leadership roles: secretary of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, member of the board of the Netherlands Respiratory Society, member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation, chair of the educational committee of the European Reference Network for Rare Lung Diseases, advisory board of the Dutch Lungfibrosis and Sarcoidosis patient associations.
Support statement: This work was supported by the Netherlands Organization for Health Research and Development (grant: 848016002). Funding information for this article has been deposited with the Crossref Funder Registry.